Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract-Reference-Cited by-同舟云学术

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract

Published:2018-02 Issue:1 Volume:11 Page:37-42
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Lee Ji Yun^ORCID,Kim Kyung^ORCID,Sung Hyun Hwan,Jeon Hwang Gyun,Jeong Byong Chang,Seo Seong Il^ORCID,Jeon Seong Soo,Lee Hyun Moo,Choi Han-Yong,Kwon Ghee-Young,Kim Kyoung-Mee,Lee Jeeyun,Lim Ho Yeong,Park Se Hoon^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008;Jung;Cancer Res Treat,2011

2. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades;Munoz;J Urol,2000

3. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update;Roupret;Eur Urol,2011

4. Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis;Gandaglia;Int J Urol,2014

5. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials;Leow;Eur Urol,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study;Cancer Research and Treatment;2024-07-15

2. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study;Journal of Urologic Oncology;2024-03-31

3. FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation Sequencing;Journal of Clinical Medicine;2024-02-25

4. TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma;The Kaohsiung Journal of Medical Sciences;2024-01-05

5. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site;Anticancer Research;2023-11